The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Development and Brain Delivery of Chitosan−PEG Nanoparticles Functionalized with the Monoclonal Antibody OX26
Open accessAbstract
The inhibition of the caspase-3 enzyme is reported to increase neuronal cell survival following cerebral ischemia. The peptide Z-DEVD-FMK is a specific caspase inhibitor, which significantly reduces vulnerability to the neuronal cell death. However, this molecule is unable to cross the blood-brain barrier (BBB) and to diffuse into the brain tissue. Thus, the development of an effective delivery system is needed to provide sufficient drug concentration into the brain to prevent cell death. Using the avidin (SA)-biotin (BIO) technology, we describe here the design of chitosan (CS) nanospheres conjugated with poly(ethylene glycol) (PEG) bearing the OX26 monoclonal antibody whose affinity for the transferrin receptor (TfR) may trigger receptor-mediated transport across the BBB. These functionalized CS-PEG-BIO-SA/OX26 nanoparticles (NPs) were characterized for their particle size, zeta potential, drug loading capacity, and release properties. Fluorescently labeled CS-PEG-BIO-SA/OX26 nanoparticles were administered systemically to mice in order to evaluate their efficacy for brain translocation. The results showed that an important amount of nanoparticles were located in the brain, outside of the intravascular compartment. These findings, which were also confirmed by electron microscopic examination of the brain tissue indicate that this novel targeted nanoparticulate drug delivery system was able to translocate into the brain tissue after iv administration. Consequently, these novel nanoparticles are promising carriers for the transport of the anticaspase peptide Z-DEVD-FMK into the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers
Calvo, P., Remu��n-L�pez, C., Vila-Jato, J. L., & Alonso, M. J. (1997) · Journal of Applied Polymer Science · doi:10.1002/(sici)1097-4628(19970103)63:1<125::aid-app13>3.0.co;2-4 · Cited by 1,856
Self-citationChitin in Nature and Technology
(1986) · Springer eBooks · doi:10.1007/978-1-4613-2167-5 · Cited by 1,020
Polysaccharide colloidal particles as delivery systems for macromolecules
Janes, K. A., Calvo, P., & Alonso, M. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00123-x · Cited by 900
Self-citationDe Campos, A. M., Sánchez, A., & Alonso, M. J. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00760-8 · Cited by 666
Self-citationLow molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice
Vila, A., Sánchez, A., Janes, K., Behrens, I., Kissel, T., Jato, J. L. V., & Alonso, M. J. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2003.09.006 · Cited by 449
Self-citationBrigger, I., Morizet, J., Aubert, G., Chacun, H., Terrier-Lacombe, M.-J., Couvreur, P., & Vassal, G. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039669 · Cited by 234
Self-citationCalvo, P., Gouritin, B., Villarroya, H., Eclancher, F., Giannavola, C., Klein, C., Andreux, J. P., & Couvreur, P. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01967.x · Cited by 164
Self-citationPreparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor
Aktaş, Y., Andrieux, K., Alonso, M. J., Calvo, P., Gürsoy, R. N., Couvreur, P., & Çapan, Y. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.03.027 · Cited by 135
Self-citation
Cited by
Polysaccharides-based nanoparticles as drug delivery systems
Liu, Z., Jiao, Y., Wang, Y., Zhou, C., & Zhang, Z. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.001 · Cited by 1,732
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Nanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Self-citation
Metadata
- Authors
- Aktaş, Y., Yemisci, M., Andrieux, K., Gürsoy, R. N., Alonso, M. J., Fernandez-Megia, E., Novoa-Carballal, R., Quiñoá, E., Riguera, R., Sargon, M. F., Çelik, H. H., Demir, A. S., Hıncal, A. A., Dalkara, T., Çapan, Y., & Couvreur, P.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-10-20
- Volume
- 16
- Issue
- 6
- Pages
- 1503-1511
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W1983818104
- Cited by
- 318
- References
- 9
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development and Brain Delivery of Chitosan−PEG Nanoparticles Functionalized with the Monoclonal Antibody OX26. https://app.cochat.ai/papers/10.1021/bc050217o
- The paper
- Aktaş, Y., Yemisci, M., Andrieux, K., Gürsoy, R. N., Alonso, M. J., Fernandez-Megia, E., Novoa-Carballal, R., Quiñoá, E., Riguera, R., Sargon, M. F., Çelik, H. H., Demir, A. S., Hıncal, A. A., Dalkara, T., Çapan, Y., & Couvreur, P. (2005). Development and Brain Delivery of Chitosan−PEG Nanoparticles Functionalized with the Monoclonal Antibody OX26. Bioconjugate Chemistry. https://doi.org/10.1021/bc050217o
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
